ワクチンアジュバント市場:2027年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年8月

ワクチンアジュバント市場:製品(微粒子、エマルジョン、病原体、サポニン)、投与経路(皮下、筋肉内)、疾患タイプ(感染症、がん)、用途(研究、商業)、用途カテゴリー – 2027年までの世界予測
Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category – Global Forecast to 2027

ページ数 206
図表数 235
種別 英文調査報告書
価格 こちらをご覧ください

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

MarketsandMarkets(マーケッツアンドマーケッツ)「ワクチンアジュバント市場:製品(微粒子、エマルジョン、病原体、サポニン)、投与経路(皮下、筋肉内)、疾患タイプ(感染症、がん)、用途(研究、商業)、用途カテゴリー – 2027年までの世界予測 – Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category – Global Forecast to 2027」は世界のワクチンアジュバント市場を調査し、主要セグメント毎に行った分析・予測結果を提供します。

主な対象セグメント

  • 製品
    • アジュバントエマルジョン
    • 病原体
    • サポニンベースのアジュバント
    • 微粒子アジュバント
    • その他のアジュバント
  • 投与方法
    • 筋肉内
    • 皮下
    • その他の投与方法
  • 疾患タイプ
    • 感染症
    • がん
    • その他
  • 用途
    • 調査
    • 商用
  • 用途カテゴリ
    • ヒト用ワクチンアジュバント
    • 動物用ワクチンアジュバント
  • 地域
    • 北米
      • 米国
      • カナダ
    • 欧州
      • ドイツ
      • 英国
      • フランス
      • イタリア
      • スペイン
      • その他の欧州
    • アジア太平洋地域
      • 中国
      • 日本
      • 韓国
      • その他のアジア太平洋地域
    • ラテンアメリカ
    • 中東

Report Overview

The vaccine adjuvants market is projected to reach USD 1.6 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period. The growth of the market is projected to be driven by factors such as the rising prevalence of infectious diseases, increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.
The adjuvant emulsions accounted for the largest share of the product segment in the vaccine adjuvants market in 2021.

Vaccine Adjuvants Market - MarketsandMarkets

Adjuvant emulsions function by generating depots that can trap antigens at the injection site. This results in slow release to continue the stimulation of the immune system. The adjuvant emulsions segment accounted for the largest share of the market in 2021. The extensive use of adjuvant emulsions in COVID-19 and other infectious diseases and the rising prevalence of infectious diseases are driving the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2021.

The infectious diseases segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.

Key players in the vaccine adjuvants market include Prominent players in the global vaccine adjuvants market are GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

“Asia Pacific: The fastest-growing region in the vaccine adjuvants market”

The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to the increasing investments in the life sciences sector and rising awareness through conferences and symposiums. In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

北米のワクチンアジュバント市場 - マーケッツアンドマーケッツ

List of Companies Profiled in the Report:
• GSK plc (UK)
• Dynavax Technologies (US)
• Novavax (US)
• Agenus Inc. (US)
• Croda International plc (UK)
• Seppic (France)
• OZ Biosciences (US)
• Phibro Animal Health Corporation (US)
• Associated British Foods plc (UK)
• InvivoGen (US)
• Merck KGaA (Germany)
• CSL Limited (Australia)
• Vertellus (US)
• Allergy Therapeutics (UK)
• Riboxx GmbH (Germany)
• CaPtivatϵ Pharmaceuticals LLC (US)
• EuBiologics Co., Ltd. (South Korea)
• Pacific GeneTech Limited (US)
• Hawaii Biotech Inc. (US)
• Vaxine Pty Ltd. (Australia)
• Creative Diagnostics (US)
• LiteVax BV (Netherlands)
• Mukta Industries (India)
• Oncovir, Inc. (US)
• TiterMax USA, Inc. (US).

Research Coverage:

This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

Scope of the Report

Report Metric

Details

Market size available for years 2020–2027
Base year considered 2021
Forecast period 2022–2027
Forecast units Value (USD)
Segments covered Product, Route of Administration, Disease Type, Application, Application Category, and Region
Geographies covered North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
Companies covered GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), Vaxine Pty Ltd. (Australia), Creative Diagnostics (US), LiteVax BV (Netherlands), Mukta Industries (India), Oncovir, Inc. (US), and TiterMax USA, Inc. (US).

This report categorizes the vaccine adjuvants market into the following segments and subsegments

By Product

  • Adjuvant Emulsions
  • Pathogen Components
  • Saponin-baased adjuvants
  • Particulate Adjuvants
  • Other Adjuvants

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Other Route of Administration

By Disease Type

  • Infectious Diseases
  • Cancer
  • Others

By Application

  • Research Applications
  • Commercial Applications

By Application Category

  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In October 2021, Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
  • In February 2021, SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.

目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 35)
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 PRIMARY RESEARCH
FIGURE 2 VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 6 VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. – 44)
FIGURE 8 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)
FIGURE 10 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET

4 PREMIUM INSIGHTS (Page No. – 48)
4.1 VACCINE ADJUVANTS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2021)
FIGURE 15 ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
FIGURE 16 ADJUVANT EMULSIONS SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of infectious diseases
5.2.1.2 Increasing use of adjuvants in vaccines
5.2.1.3 Collaborations and partnerships among market players for development of vaccine adjuvants
5.2.1.4 Increasing number of COVID-19 vaccines in development pipeline
FIGURE 19 TOP LOCATIONS BASED ON NUMBER OF COVID-19 VACCINES IN DEVELOPMENT PIPELINE (AS OF OCTOBER 2021)
5.2.1.5 Increasing focus on immunization programs
5.2.2 RESTRAINTS
5.2.2.1 Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing
5.2.3 OPPORTUNITIES
5.2.3.1 Rising funding for vaccines and infectious disease research activities
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
5.2.3.2 Development of plant-based vaccine adjuvants
5.2.4 CHALLENGES
5.2.4.1 Side effects and high toxicity of adjuvants
5.3 RANGES/SCENARIOS
FIGURE 20 SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF VACCINE ADJUVANTS MARKET
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS
5.5.2 AVERAGE SELLING PRICE TREND
5.6 TECHNOLOGY ANALYSIS
5.6.1 SUPERCRITICAL FLUID EXTRACTION TECHNOLOGY
5.7 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
FIGURE 23 ECOSYSTEM ANALYSIS
TABLE 4 SUPPLY CHAIN ECOSYSTEM
5.9 PATENT ANALYSIS
FIGURE 24 PATENT APPLICATIONS RELATED TO VACCINE ADJUVANTS MARKET, JANUARY 2012–AUGUST 2022
5.10 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 5 LIST OF CONFERENCES AND EVENTS IN VACCINE ADJUVANTS MARKET
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 DEGREE OF COMPETITION
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ON BUYING PROCESS OF VACCINE ADJUVANTS
5.13.2 BUYING CRITERIA FOR VACCINE ADJUVANTS
FIGURE 26 BUYING CRITERIA FOR VACCINE ADJUVANTS

6 VACCINE ADJUVANTS MARKET, BY PRODUCT (Page No. – 67)
6.1 INTRODUCTION
TABLE 7 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 ADJUVANT EMULSIONS
6.2.1 ADJUVANT EMULSIONS FUNCTION BY GENERATING DEPOTS THAT TRAP ANTIGENS AT INJECTION SITE
TABLE 8 ADJUVANT EMULSIONS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 PATHOGEN COMPONENTS
6.3.1 PROMINENT MARKET PLAYERS DEVELOPING BACTERIA-DERIVED ADJUVANTS—KEY FACTOR SUPPORTING MARKET GROWTH
TABLE 12 PATHOGEN COMPONENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SAPONIN-BASED ADJUVANTS
6.4.1 GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET
TABLE 16 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 PARTICULATE ADJUVANTS
6.5.1 MINERAL-BASED ADJUVANTS MOST WIDELY USED AMONG PARTICULATE ADJUVANTS
TABLE 20 PARTICULATE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 21 NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 OTHER ADJUVANTS
TABLE 24 OTHER VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION (Page No. – 79)
7.1 INTRODUCTION
TABLE 28 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
7.2 INTRAMUSCULAR
7.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT
TABLE 29 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION
TABLE 30 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 SUBCUTANEOUS
7.3.1 ADVANTAGES OFFERED BY SUBCUTANEOUS ADMINISTRATION TO DRIVE MARKET
TABLE 34 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION
TABLE 35 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 OTHER ROUTES OF ADMINISTRATION
TABLE 39 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)

8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE (Page No. – 87)
8.1 INTRODUCTION
TABLE 43 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
8.2 INFECTIOUS DISEASES
8.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 44 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CANCER
8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH
TABLE 48 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 OTHER DISEASES
TABLE 52 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)

9 VACCINE ADJUVANTS MARKET, BY APPLICATION (Page No. – 95)
9.1 INTRODUCTION
TABLE 56 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 RESEARCH APPLICATIONS
9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET
TABLE 57 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 COMMERCIAL APPLICATIONS
9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH
TABLE 61 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

10 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY (Page No. – 101)
10.1 INTRODUCTION
TABLE 65 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
10.2 HUMAN VACCINE ADJUVANTS
10.2.1 INCREASE IN PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS
TABLE 66 HUMAN VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 VETERINARY VACCINE ADJUVANTS
10.3.1 DEVELOPMENT OF ANIMAL VACCINES GOVERNED BY FEWER REGULATORY ASPECTS
TABLE 70 VETERINARY VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

11 VACCINE ADJUVANTS MARKET, BY REGION (Page No. – 107)
11.1 INTRODUCTION
TABLE 74 VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
TABLE 75 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 79 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 80 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 US dominates North American vaccine adjuvants market
TABLE 81 US: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 82 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 83 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 84 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 85 US: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Increasing government funding for vaccine research to drive market
TABLE 86 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 87 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 88 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 89 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 90 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 91 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 93 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 95 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 96 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Growing funding from government organizations to drive market
TABLE 97 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 98 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 99 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 100 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 101 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Rising investments in vaccine development to boost market growth
TABLE 102 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 103 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 104 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 105 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 106 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Focus on new vaccine development to drive market
TABLE 107 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 108 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 109 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 110 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 111 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increase in R&D for vaccines and government initiatives—key factors driving market
TABLE 112 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 113 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 114 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 115 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 116 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing investments in vaccine development by government and private organizations to drive market
TABLE 117 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 118 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 119 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 120 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 121 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 122 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 123 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 124 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 125 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 126 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT
TABLE 127 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 128 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 129 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 130 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 131 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 132 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Government support and strategic initiatives by key players to strengthen biotechnology sector
TABLE 133 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 134 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 135 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 136 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 137 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Government initiatives for vaccines to boost market
TABLE 138 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 139 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 140 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 141 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 142 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growth of the biotechnology sector and development of new vaccines to drive market
TABLE 143 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 144 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 145 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 146 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 147 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 148 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 149 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 150 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 151 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 152 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 SURGE IN PHARMACEUTICAL AND BIOTECHNOLOGY RESEARCH— KEY FACTOR DRIVING MARKET
TABLE 153 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 154 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 155 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 156 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST AND AFRICA
11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO DRIVE MARKET
TABLE 158 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 159 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 160 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 161 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 162 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. – 149)
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 29 VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 30 VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
TABLE 163 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION
12.4 REVENUE ANALYSIS
FIGURE 31 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 32 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX, 2021
12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
12.6.1 COMPANY FOOTPRINT (25 COMPANIES)
TABLE 164 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
12.6.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 165 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
12.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
TABLE 166 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
12.7 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
FIGURE 33 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021
12.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 167 DETAILED LIST OF KEY STARTUP/SMES
TABLE 168 COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)
12.9 COMPETITIVE SCENARIO AND TRENDS
12.9.1 PRODUCT LAUNCHES
TABLE 169 KEY PRODUCT LAUNCHES, JANUARY 2019–JULY 2022
12.9.2 DEALS
TABLE 170 KEY DEALS, JANUARY 2019–JULY 2022
12.9.3 OTHER KEY DEVELOPMENTS
TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2019–JULY 2022

13 COMPANY PROFILES (Page No. – 164)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 GSK PLC
TABLE 172 GSK PLC: BUSINESS OVERVIEW
FIGURE 34 GSK PLC: COMPANY SNAPSHOT (2021)
13.1.2 DYNAVAX TECHNOLOGIES
TABLE 173 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 35 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2021)
13.1.3 NOVAVAX
TABLE 174 NOVAVAX: BUSINESS OVERVIEW
FIGURE 36 NOVAVAX: COMPANY SNAPSHOT (2021)
13.1.4 AGENUS INC.
TABLE 175 AGENUS INC.: BUSINESS OVERVIEW
FIGURE 37 AGENUS INC.: COMPANY SNAPSHOT (2021)
13.1.5 CRODA INTERNATIONAL PLC
TABLE 176 CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW
FIGURE 38 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2021)
13.1.6 SEPPIC (SUBSIDIARY OF AIR LIQUIDE GROUP)
TABLE 177 AIR LIQUIDE GROUP: BUSINESS OVERVIEW
FIGURE 39 AIR LIQUIDE: COMPANY SNAPSHOT (2021)
13.1.7 PHIBRO ANIMAL HEALTH CORPORATION
TABLE 178 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW
FIGURE 40 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2020)
13.1.8 SPI PHARMA (SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
TABLE 179 ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW
FIGURE 41 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2021)
13.1.9 CSL LIMITED
TABLE 180 CSL LIMITED: BUSINESS OVERVIEW
FIGURE 42 CSL LIMITED: COMPANY SNAPSHOT (2021)
13.1.10 MERCK KGAA
TABLE 181 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021)
13.1.11 OZ BIOSCIENCES
TABLE 182 OZ BIOSCIENCES: BUSINESS OVERVIEW
13.1.12 INVIVOGEN
TABLE 183 INVIVOGEN: BUSINESS OVERVIEW
13.1.13 ALLERGY THERAPEUTICS
TABLE 184 ALLERGY THERAPEUTICS: BUSINESS OVERVIEW
FIGURE 44 ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2020)
13.1.14 VERTELLUS
TABLE 185 VERTELLUS: BUSINESS OVERVIEW
13.1.15 EUBIOLOGICS CO., LTD.
TABLE 186 EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW
13.1.16 PACIFIC GENETECH LIMITED
TABLE 187 PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW
13.1.17 HAWAII BIOTECH INC.
TABLE 188 HAWAII BIOTECH INC.: BUSINESS OVERVIEW
13.1.18 RIBOXX GMBH
TABLE 189 RIBOXX GMBH: BUSINESS OVERVIEW
13.1.19 CAPTIVATE PHARMACEUTICALS LLC
TABLE 190 CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW
13.1.20 VAXINE PTY LTD.
TABLE 191 VAXINE PTY LTD.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER COMPANIES
13.2.1 CREATIVE DIAGNOSTICS
13.2.2 LITEVAX BV
13.2.3 MUKTA INDUSTRIES
13.2.4 ONCOVIR, INC.
13.2.5 TITERMAX USA, INC.

14 APPENDIX (Page No. – 208)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com